{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:03:48Z","timestamp":1793714628186,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1038\/s41591-024-03304-z","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T06:02:04Z","timestamp":1728453724000},"page":"332-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":201,"title":["AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3966-6303","authenticated-orcid":false,"given":"Jerry R.","family":"Mendell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8779-3220","authenticated-orcid":false,"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio M.","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Ciafaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0659-1417","authenticated-orcid":false,"given":"Hirofumi","family":"Komaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-4301","authenticated-orcid":false,"given":"Carmen","family":"Leon-Astudillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8416-9335","authenticated-orcid":false,"given":"Crystal","family":"Proud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Schara-Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3065-3956","authenticated-orcid":false,"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"Zaidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7163-0075","authenticated-orcid":false,"given":"Maitea","family":"Guridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3907-9709","authenticated-orcid":false,"given":"Damon R.","family":"Asher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Darton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-8993","authenticated-orcid":false,"given":"Rachael A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teji","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob S.","family":"Elkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-5177","authenticated-orcid":false,"given":"Louise R.","family":"Rodino-Klapac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"3304_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan, D., Goemans, N., Takeda, S., Mercuri, E. & Aartsma-Rus, A. Duchenne muscular dystrophy. Nat. Rev. Dis. Prim. 7, 13 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"3304_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-012-0332-1","volume":"13","author":"LR Rodino-Klapac","year":"2013","unstructured":"Rodino-Klapac, L. R., Mendell, J. R. & Sahenk, Z. Update on the treatment of Duchenne muscular dystrophy. Curr. Neurol. Neurosci. Rep. 13, 332 (2013).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"3304_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald, C. M. et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391, 451\u2013461 (2018).","journal-title":"Lancet"},{"key":"3304_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 17, 251\u2013267 (2018).","journal-title":"Lancet Neurol."},{"key":"3304_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","volume":"8","author":"CM McDonald","year":"2021","unstructured":"McDonald, C. M. et al. Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial. J. Neuromuscul. Dis. 8, 989\u20131001 (2021).","journal-title":"J. Neuromuscul. Dis."},{"key":"3304_CR6","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus, A. et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum. Mutat. 30, 293\u2013299 (2009).","journal-title":"Hum. Mutat."},{"key":"3304_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637\u2013647 (2013).","journal-title":"Ann. Neurol."},{"key":"3304_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77\u201393 (2010).","journal-title":"Lancet Neurol."},{"key":"3304_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nm0302-253","volume":"8","author":"S Harper","year":"2002","unstructured":"Harper, S. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253\u2013261 (2002).","journal-title":"Nat. Med."},{"key":"3304_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/sj.mt.6300027","volume":"15","author":"MZ Salva","year":"2007","unstructured":"Salva, M. Z. et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320\u2013329 (2007).","journal-title":"Mol. Ther."},{"key":"3304_CR11","unstructured":"US Food and Drug Administration. ELEVIDYS (delandistrogene moxeparvovec-rokl). Highlights of prescribing information. https:\/\/www.fda.gov\/media\/169679\/download"},{"key":"3304_CR12","unstructured":"US Food and Drug Administration. FDA expands approval of gene therapy for patients with Duchenne muscular dystrophy. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-expands-approval-gene-therapy-patients-duchenne-muscular-dystrophy (2024)."},{"key":"3304_CR13","unstructured":"UAE Ministry of Health and Prevention. Registered Medical Product Directory. https:\/\/mohap.gov.ae\/en\/more\/registered-medical-product-directory (2024)."},{"key":"3304_CR14","unstructured":"Qatar Ministry of Public Health. Qatar National Formulary. https:\/\/www.moph.gov.qa\/english\/OurServices\/advancedsearch\/Pages\/servicesdetails.aspx?serviceId=234 (2024)."},{"key":"3304_CR15","unstructured":"NHRA Bahrain. Pharmacy & Pharmaceutical Products Regulation (PPR). https:\/\/www.nhra.bh\/Departments\/PPR\/ (2024)."},{"key":"3304_CR16","unstructured":"Oman Ministry of Health. List of registered pharmaceutical manufacturers and products. https:\/\/www.moh.gov.om\/en\/hospitals-directorates\/directorates-and-centers-at-hq\/drug-safety-center\/#Resources (2024)."},{"key":"3304_CR17","unstructured":"Kuwait Ministry of Health. Drug and Dietary Supplement Price List. https:\/\/e.gov.kw\/sites\/kgoenglish\/Pages\/eServices\/MOH\/DrugFoodSupplementPrices.aspx (2024)."},{"key":"3304_CR18","unstructured":"Ministry of Health Israel. The Israeli Drug Registry. https:\/\/israeldrugs.health.gov.il\/#!\/byDrug (2024)."},{"key":"3304_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"J Mendell","year":"2020","unstructured":"Mendell, J. et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 77, 1121\u20131131 (2020).","journal-title":"JAMA Neurol."},{"key":"3304_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell, J. R. et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front. Cell Dev. Biol. 11, 1167762 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"3304_CR21","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman, C. M. et al. Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann. Neurol. 94, 955\u2013968 (2023).","journal-title":"Ann. Neurol."},{"key":"3304_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/mus.27955","volume":"69","author":"JR Mendell","year":"2024","unstructured":"Mendell, J. R. et al. Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial. Muscle Nerve 69, 93\u201398 (2024).","journal-title":"Muscle Nerve"},{"key":"3304_CR23","unstructured":"A gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 (delandistrogene moxeparvovec) in participants with Duchenne muscular dystrophy (DMD) (EMBARK). https:\/\/clinicaltrials.gov\/ct2\/show\/\/NCT05096221"},{"key":"3304_CR24","unstructured":"Khan, S. et al. T-cell response to micro-dystrophin in a patient treated with delandistrogene moxeparvovec gene therapy: a case of immune-mediated myositis. In 28th International Annual Congress of the World Muscle Society (2023); https:\/\/investorrelations.sarepta.com\/static-files\/51d79e1a-7ef7-46c6-93e3-c63b7be11238"},{"key":"3304_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dmcn.15176","volume":"64","author":"AA Zambon","year":"2022","unstructured":"Zambon, A. A. et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev. Med. Child Neurol. 64, 979\u2013988 (2022).","journal-title":"Dev. Med. Child Neurol."},{"key":"3304_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl, H. C. J. Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. 13, 975803 (2022).","journal-title":"Front. Immunol."},{"key":"3304_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/17512433.2014.852065","volume":"7","author":"F Salmon","year":"2014","unstructured":"Salmon, F., Grosios, K. & Petry, H. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera\u00ae). Expert Rev. Clin. Pharm. 7, 53\u201365 (2014).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"3304_CR28","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/v15112168","volume":"15","author":"C Chan","year":"2023","unstructured":"Chan, C., Harris, K. K., Zolotukhin, S. & Keeler, G. D. Rational design of AAV-rh74, AAV3B, and AAV8 with limited liver targeting. Viruses 15, 2168 (2023).","journal-title":"Viruses"},{"key":"3304_CR29","first-page":"e36197","volume":"15","author":"T Ogbonmide","year":"2023","unstructured":"Ogbonmide, T. et al. Gene therapy for spinal muscular atrophy (SMA): a review of current challenges and safety considerations for onasemnogene abeparvovec (zolgensma). Cureus 15, e36197 (2023).","journal-title":"Cureus"},{"key":"3304_CR30","unstructured":"US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi). Highlights of prescribing information. https:\/\/www.fda.gov\/media\/126109\/download?attachment"},{"key":"3304_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/17562864221149781","volume":"16","author":"NL Goedeker","year":"2023","unstructured":"Goedeker, N. L. et al. Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy. Ther. Adv. Neurol. Disord. 16, 17562864221149781 (2023).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"3304_CR32","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","volume":"78","author":"G Gao","year":"2004","unstructured":"Gao, G. et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78, 6381\u20136388 (2004).","journal-title":"J. Virol."},{"key":"3304_CR33","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1089\/hum.2023.194","volume":"35","author":"E Kropf","year":"2024","unstructured":"Kropf, E., Markusic, D. M., Majowicz, A., Mingozzi, F. & Kuranda, K. Complement system response to adeno-associated virus vector gene therapy. Hum. Gene Ther. 35, 425\u2013438 (2024).","journal-title":"Hum. Gene Ther."},{"key":"3304_CR34","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.omtm.2024.101195","volume":"32","author":"RA Potter","year":"2024","unstructured":"Potter, R. A. et al. Use of plasmapheresis to lower anti-AAV antibodies in nonhuman primates with pre-existing immunity to AAVrh74. Mol. Ther. Methods Clin. Dev. 32, 101195 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"3304_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","volume":"153","author":"JR Mendell","year":"2024","unstructured":"Mendell, J. R. et al. Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr. Neurol. 153, 11\u201318 (2024).","journal-title":"Pediatr. Neurol."},{"key":"3304_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1089\/hum.2022.081","volume":"34","author":"S Verma","year":"2023","unstructured":"Verma, S. et al. Seroprevalence of adeno-associated virus neutralizing antibodies in males with Duchenne muscular dystrophy. Hum. Gene Ther. 34, 430\u2013438 (2023).","journal-title":"Hum. Gene Ther."},{"key":"3304_CR37","unstructured":"A gene transfer therapy study to evaluate the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) following imlifidase infusion in participants with Duchenne muscular dystrophy (DMD) determined to have pre-existing antibodies to recombinant adeno-associated virus serotype (rAAVrh74). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT06241950"},{"key":"3304_CR38","doi-asserted-by":"publisher","first-page":"e0232870","DOI":"10.1371\/journal.pone.0232870","volume":"15","author":"N Goemans","year":"2020","unstructured":"Goemans, N. et al. Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: a multi-institutional collaboration. PLoS ONE 15, e0232870 (2020).","journal-title":"PLoS ONE"},{"key":"3304_CR39","doi-asserted-by":"publisher","first-page":"e0221097","DOI":"10.1371\/journal.pone.0221097","volume":"14","author":"F Muntoni","year":"2019","unstructured":"Muntoni, F. et al. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS ONE 14, e0221097 (2019).","journal-title":"PLoS ONE"},{"key":"3304_CR40","first-page":"CD003725","volume":"2016","author":"E Matthews","year":"2016","unstructured":"Matthews, E., Brassington, R., Kuntzer, T., Jichi, F. & Manzur, A. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 2016, CD003725 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"3304_CR41","doi-asserted-by":"publisher","first-page":"e0265879","DOI":"10.1371\/journal.pone.0265879","volume":"17","author":"N Ferizovic","year":"2022","unstructured":"Ferizovic, N. et al. Prognostic indicators of disease progression in Duchenne muscular dystrophy: a literature review and evidence synthesis. PLoS ONE 17, e0265879 (2022).","journal-title":"PLoS ONE"},{"key":"3304_CR42","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/mus.26161","volume":"58","author":"H Arora","year":"2018","unstructured":"Arora, H. et al. Longitudinal timed function tests in Duchenne muscular dystrophy: imagingDMD cohort natural history. Muscle Nerve 58, 631\u2013638 (2018).","journal-title":"Muscle Nerve"},{"key":"3304_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0408-z","volume":"15","author":"L Merlini","year":"2015","unstructured":"Merlini, L. & Sabatelli, P. Improving clinical trial design for Duchenne muscular dystrophy. BMC Neurol. 15, 153 (2015).","journal-title":"BMC Neurol."},{"key":"3304_CR44","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3233\/JND-210743","volume":"9","author":"L Servais","year":"2022","unstructured":"Servais, L., Yen, K., Guridi, M. & Lukawy, J. Stride velocity 95th centile: insights into gaining regulatory qualification of the first wearable-derived digital endpoint for use in Duchenne muscular dystrophy trials. J. Neuromuscul. Dis. 9, 335\u2013346 (2022).","journal-title":"J. Neuromuscul. Dis."},{"key":"3304_CR45","unstructured":"European Medicines Agency. Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne muscular dystrophy measured by a valid and suitable wearable device. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy_en.pdf (2019)."},{"key":"3304_CR46","unstructured":"European Medicines Agency. Qualification opinion for stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne muscular dystrophy studies. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne_en.pdf (2023)."},{"key":"3304_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","volume":"79","author":"JR Mendell","year":"2016","unstructured":"Mendell, J. R. et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257\u2013271 (2016).","journal-title":"Ann. Neurol."},{"key":"3304_CR48","unstructured":"A gene transfer therapy study to evaluate the safety and efficacy of SRP-9001 (delandistrogene moxeparvovec) in non-ambulatory and ambulatory participants with Duchenne muscular dystrophy (DMD) (ENVISION). https:\/\/clinicaltrials.gov\/study\/NCT05881408"},{"key":"3304_CR49","unstructured":"A two-part, open-label systemic gene delivery study to evaluate the safety and expression of RO7494222 (SRP-9001) in subjects under the age of four with Duchenne muscular dystrophy (ENVOL) (2022-000691-19). https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2022-000691-19\/FR"},{"key":"3304_CR50","unstructured":"A gene delivery study to evaluate the safety of and expression from SRP-9001 in Duchenne muscular dystrophy (DMD) (ENDEAVOR). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04626674"},{"key":"3304_CR51","unstructured":"A gene transfer therapy study to evaluate the safety of delandistrogene moxeparvovec (SRP-9001) in participants with Duchenne muscular dystrophy (DMD). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03375164"},{"key":"3304_CR52","unstructured":"A randomized, double-blind, placebo-controlled study of SRP-9001 for Duchenne muscular dystrophy (DMD). https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03769116"},{"key":"3304_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2020.1725469","volume":"20","author":"D Asher","year":"2020","unstructured":"Asher, D. et al. Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opin. Biol. Ther. 20, 263\u2013274 (2020).","journal-title":"Expert Opin. Biol. Ther."},{"key":"3304_CR54","unstructured":"US Food and Drug Administration. Collection of race and ethnicity data in clinical trials and clinical studies for FDA-regulated medical products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical (2024)."},{"key":"3304_CR55","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","volume":"90","author":"JS Charleston","year":"2018","unstructured":"Charleston, J. S. et al. Eteplirsen treatment for Duchenne muscular dystrophy: exon skipping and dystrophin production. Neurology 90, e2146\u2013e2154 (2018).","journal-title":"Neurology"},{"key":"3304_CR56","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/01621459.1984.10478093","volume":"79","author":"LJ Wei","year":"1984","unstructured":"Wei, L. J. & Lachin, J. M. Two-sample asymptotically distribution-free tests for incomplete multivariate observations. J. Am. Stat. Assoc. 79, 653\u2013661 (1984).","journal-title":"J. Am. Stat. Assoc."},{"key":"3304_CR57","doi-asserted-by":"publisher","first-page":"e1921306","DOI":"10.1001\/jamanetworkopen.2019.21306","volume":"3","author":"D Li","year":"2020","unstructured":"Li, D. et al. Assessment of treatment effect with multiple outcomes in 2 clinical trials of patients with Duchenne muscular dystrophy. JAMA Netw. Open 3, e1921306 (2020).","journal-title":"JAMA Netw. Open"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03304-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03304-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03304-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:03:56Z","timestamp":1737482636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03304-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3304"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03304-z","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R.M. received study funding from Sarepta Therapeutics while at Nationwide Children\u2019s Hospital at the time of the study and is currently an employee of Sarepta Therapeutics. J.R.M. is a co-inventor of AAVrh74.MHCK7.micro-dys technology. F.M. has received honoraria and grants from Sarepta Therapeutics for participating at symposia and advisory boards and is involved as an investigator in Sarepta Therapeutics clinical trials. He reports participation in advisory boards for Novartis, F. Hoffmann-La Roche, Ltd., Edgewise Therapeutics, Dyne Therapeutics, Pfizer, PTC Therapeutics and Italfarmaco. C.M.M. reports grants from Capricor Therapeutics, Catabasis, Edgewise Therapeutics, Epirium Bio, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics and has a consultancy\/advisory role with Biomarin, Capricor Therapeutics, Catalyst, Edgewise Therapeutics, Italfarmaco, PTC Therapeutics, F. Hoffmann-La Roche, Ltd., Santhera Pharmaceuticals and Sarepta Therapeutics. He has received honoraria from PTC Therapeutics and Sarepta Therapeutics. E.M.M. has received fees from AveXis, Biogen and F. Hoffmann-La Roche, Ltd. E.C. has received honoraria from Sarepta Therapeutics for participating in advisory boards and research and\/or grant support from the Centers for Disease Control and Prevention, CureSMA, the Muscular Dystrophy Association, the National Institutes of Health, Orphazyme, the Patient-Centered Outcomes Research Institute, Parent Project Muscular Dystrophy, PTC Therapeutics, Santhera, Sarepta Therapeutics and the US Food and Drug Administration. H.K. has received grants from Sarepta Therapeutics, Pfizer, PTC Therapeutics, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Nippon Shinyaku Co., Ltd. and Kaneka Corporation. H.K. has received fees from Sarepta Therapeutics, Pfizer, PTC Therapeutics, Chugai Pharmaceutical Co., Nippon Shinyaku Co. and Kaneka Corporation. C.L.-A. is an investigator in Sarepta Therapeutics clinical trials and a sub-investigator in studies sponsored by Pfizer, SolidBioSciences, Edgewise Therapeutics, Italfarmaco and Genentech\/Roche. A.N. has received fees from AveXis, Biogen and F. Hoffmann-La Roche, Ltd. C.P. participates on an advisory board and is a consultant for Biogen, Sarepta Therapeutics, AveXis\/Novartis Gene Therapies, Genentech\/Roche and Scholar Rock; serves as a speaker for Biogen; and is a principal investigator of studies sponsored by AveXis\/Novartis Gene Therapies, AMO Pharma, Astellas, Biogen, CSL Behring, Fibrogen, PTC Therapeutics, Pfizer, Sarepta Therapeutics and Scholar Rock. U.S.-S. has received honoraria for counseling and participating in invited talks from Sarepta Therapeutics and F. Hoffmann-La Roche, Ltd. A.V. has a consultancy\/advisory role with AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, UCB Pharma, Catalyst and Scholar Rock; has received research funding from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, the Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio and Sarepta Therapeutics; and has other relationship(s) with MedLink Neurology for editorial services. C.M.Z. has received research support from Biogen and Novartis and has served on an advisory board for Sarepta Therapeutics. M.G., C.W. and P.F. are employees of F. Hoffmann-La Roche, Ltd. and may have stock options. A.P.M. and C.R. are employees of Roche Products, Ltd. and may have stock options in F. Hoffmann-La Roche, Ltd. D.R.A., E.D., S.M., R.A.P., T.S., W.Z. and J.S.E. are employees of Sarepta Therapeutics and may have stock options. L.R.R.-K. is an employee of Sarepta Therapeutics and may have stock options. In addition, she is a co-inventor of AAVrh74.MHCK7.micro-dys technology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}